Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Project 6
- Development stage
- Preclinical
- Lead developer
- Chongqing Medical Engineering Institute
- Modality
- Small Molecules
01
Overview
Project 6 is a preclinical small molecule drug candidate under development by Chongqing Pharmaceutical (Chongqing Pharmaceutical Research Institute) for the treatment of cancer. The program is designed to target and inhibit mechanisms of tumor immune evasion, the biological processes through which malignant cells circumvent the host's immune surveillance. By counteracting these evasion strategies, the therapy aims to restore the immune system's capacity to identify and destroy tumor cells. As of early 2024, the specific molecular target and detailed mechanism of action remain undisclosed by the developer.
- Other names
- Chongqing Pharmaceutical-Immune evasion-small molecule-Cancer/Tumor
Beyond the preview
Go deeper on Project 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Project 6.